KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Revenue (2019 - 2025)

Historic Revenue for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $622.0 million.

  • Royalty Pharma's Revenue rose 477.54% to $622.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.4 billion, marking a year-over-year increase of 506.35%. This contributed to the annual value of $2.4 billion for FY2025, which is 506.35% up from last year.
  • Royalty Pharma's Revenue amounted to $622.0 million in Q4 2025, which was up 477.54% from $609.3 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Revenue ranged from a high of $684.0 million in Q1 2023 and a low of $536.0 million during Q2 2022
  • For the 5-year period, Royalty Pharma's Revenue averaged around $576.2 million, with its median value being $570.6 million (2021).
  • Its Revenue has fluctuated over the past 5 years, first soared by 2169.24% in 2023, then crashed by 1695.88% in 2024.
  • Royalty Pharma's Revenue (Quarter) stood at $575.7 million in 2021, then fell by 1.73% to $565.7 million in 2022, then rose by 5.36% to $596.1 million in 2023, then fell by 0.41% to $593.6 million in 2024, then grew by 4.78% to $622.0 million in 2025.
  • Its Revenue was $622.0 million in Q4 2025, compared to $609.3 million in Q3 2025 and $578.7 million in Q2 2025.